Advanced Delay Testing Deployed to Address Challenges at 40nm

Synopsys, Inc. (NASDAQ:SNPS), a world leader in software and IP for semiconductor design and manufacturing, today announced that Toshiba Corporation deployed Synopsys' test solution to exceed the rigorous quality demands for its 65-nanometer (nm) multimedia chips. Toshiba engineers employed Synopsys' TetraMAX(R) automatic test pattern generation (ATPG) solution to achieve ultra-high test quality. The designs benefited from new test automation that fully utilizes on-chip clocking circuitry to improve defect testing without impacting pattern count or test time. To lower test costs, Toshiba's design engineers also used Synopsys' DFT MAX compression technology to reduce both test time and test data volume by 50-100X. Toshiba's success in meeting its test goals is now driving deployment of the Synopsys test solution for 40-nm designs, which require advanced timing-driven ATPG to achieve very low defective parts per million (DPPM).

"Our design team needed to ensure the multimedia chips could be thoroughly tested without imposing costly changes to our test infrastructure," said Takashi Yoshimori, Assistant Chief Technology Executive of SoC Design, Semiconductor Company, Toshiba Corporation. "Using DFT MAX compression and TetraMAX ATPG allowed us to achieve all of our quality and cost goals on schedule."

Most systems-on-chip (SoC) designs today rely on many internally-derived clocks operating at different frequencies. To achieve very high defect coverage during test, these internal clocks must be properly synchronized to account for inter-domain fault effects -- a time-consuming process that requires substantial design resources. New automation in TetraMAX ATPG utilizes existing on-chip clocking logic to improve test quality for SoCs containing multiple clock domains, making it feasible for designers to generate high-quality at-speed tests quickly and cost-effectively. Designers also benefit from using timing information generated by Synopsys' industry-leading PrimeTime(R) static timing analysis solution. Integration of the Synopsys test solution in the Galaxy(TM) Implementation Platform is designed to ensure predictable quality-of-results that help eliminate costly, time-consuming design iterations between synthesis and physical implementation.

"Synopsys' continued investment in advanced test technologies, such as timing-driven pattern generation, is helping companies like Toshiba deliver products with higher reliability than was previously possible," said Antun Domic, senior vice president and general manager of Synopsys' Implementation Group. "Moreover, Toshiba's success in meeting its high-quality test goals cost-effectively and on-time reflects the benefits our customers derive from having DFT fully encapsulated in the Galaxy Implementation Platform."

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Synopsys, Inc.. (2019, February 14). Advanced Delay Testing Deployed to Address Challenges at 40nm. AZoNano. Retrieved on November 21, 2024 from https://www.azonano.com/news.aspx?newsID=11196.

  • MLA

    Synopsys, Inc.. "Advanced Delay Testing Deployed to Address Challenges at 40nm". AZoNano. 21 November 2024. <https://www.azonano.com/news.aspx?newsID=11196>.

  • Chicago

    Synopsys, Inc.. "Advanced Delay Testing Deployed to Address Challenges at 40nm". AZoNano. https://www.azonano.com/news.aspx?newsID=11196. (accessed November 21, 2024).

  • Harvard

    Synopsys, Inc.. 2019. Advanced Delay Testing Deployed to Address Challenges at 40nm. AZoNano, viewed 21 November 2024, https://www.azonano.com/news.aspx?newsID=11196.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.